[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 15, 1995

Identification of the von Hippel-Lindau (VHL) GeneIts Role in Renal Cancer

Author Affiliations

From the Urologic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Md (Dr Linehan), and the Laboratory of Immunobiology, Frederick (Md) Cancer Research and Development Center, National Cancer Institute (Drs Lerman and Zbar).

JAMA. 1995;273(7):564-570. doi:10.1001/jama.1995.03520310062031
Abstract

RENAL carcinoma, the most common cancer of the kidney, occurs in over 27000 individuals in the United States each year and is responsible for over 11000 deaths annually.1 The incidence of renal carcinoma worldwide has been increasing at an annual rate of approximately 2%.1 Although renal carcinoma has been reported in children as young as 3 years, it most commonly occurs in adults between the ages of 50 and 70 years.2 Renal carcinoma affects males twice as frequently as females and accounts for approximately 3% of adult cancers. Although a number of hormonal, environmental, cellular, and genetic factors have been evaluated, little is known about the etiology of renal cancer.3 There is an increased incidence of renal cancer among workers exposed to asbestos and among leather workers,4,5 and a strong correlation has been found with cigarette smoking.6,7 In patients with end-stage renal disease, particularly

First Page Preview View Large
First page PDF preview
First page PDF preview
×